Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis
Open Access
- 8 November 2023
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , e1280-e1289
Abstract
Context: Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, but the comparative outcomes of targeted treatment remain unclear. Objective: To compare the clinical outcomes in patients treated for primary aldosteronism over time. Methods: Medline and EMBASE were searched. Original studies reporting the incidence of mortality, major adverse cardiovascular outcomes (MACE), progression to chronic kidney disease, or diabetes following adrenalectomy vs medical therapy were selected. Two reviewers independently abstracted data and assessed study quality. Standard meta-analyses were conducted using random-effects models to estimate relative differences. Time to benefit meta-analyses were conducted by fitting Weibull survival curves to estimate absolute risk differences and pooled using random-effects models. Results: 15 541 patients (16 studies) with PA were included. Surgery was consistently associated with an overall lower risk of death (hazard ratio [HR] 0.34, 95% CI 0.22-0.54) and MACE (HR 0.55, 95% CI 0.36-0.84) compared with medical therapy. Surgery was associated with a significantly lower risk of hospitalization for heart failure (HR 0.48 95% CI 0.34-0.70) and progression to chronic kidney disease (HR 0.62 95% CI 0.39-0.98), and nonsignificant reductions in myocardial infarction and stroke. In absolute terms, 200 patients would need to be treated with surgery instead of medical therapy to prevent 1 death after 12.3 (95% CI 3.1-48.7) months. Conclusion: Surgery is associated with lower all-cause mortality and MACE than medical therapy for PA. For most patients, the long-term surgical benefits outweigh the short-term perioperative risks.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT-159533)
- Heart and Stroke Foundation of Canada’s National New Investigator Award
- Lorna Jocelyn Wood Chair in Kidney Research
This publication has 70 references indexed in Scilit:
- Risk Factors Associated with a Low Glomerular Filtration Rate in Primary AldosteronismThe Journal of Clinical Endocrinology & Metabolism, 2009
- Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJournal of Clinical Epidemiology, 2008
- The "number needed to treat" turns 20 -- and continues to be used and misusedCanadian Medical Association Journal, 2008
- Estimating the relative hazard by the ratio of logarithms of event-free proportionsContemporary Clinical Trials, 2008
- Cardiovascular Outcomes in Patients With Primary Aldosteronism After TreatmentArchives of internal medicine (1960), 2008
- Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary AldosteronismHypertension, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Evidence for an increased rate of cardiovascular events in patients with primary aldosteronismJACC, 2005
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997